KYMR - Kymera Therapeutics, Inc.

QQQ $ 617.50 $ 6.52 (1.07 %)

DIA $ 472.45 $ 4.92 (1.05 %)

SPY $ 677.25 $ 5.49 (0.82 %)

TLT $ 91.47 $ 0.04 (0.04 %)

GLD $ 378.59 $ -1.27 (-0.34 %)

Previous Close

$ 58.56

Open

$ 59.11

Bid

$ 54.00 x 5

Ask

$ 62.24 x 150

Day's Range

$ 58.06 - $ 59.60

52 Week Range

$ 19.45 - $ 63.96

Volume

424,770

Average Volume

Market Cap

4.19B

Beta (5Y Monthly)

$ 2.15

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-11-2025	06-30-2025	10-Q
2	05-09-2025	03-31-2025	10-Q
3	02-27-2025	01-01-1970	10-K
4	10-31-2024	09-30-2024	10-Q
5	08-07-2024	06-30-2024	10-Q
6	05-02-2024	03-31-2024	10-Q
7	02-22-2024	12-31-2023	10-K
8	11-02-2023	09-30-2023	10-Q
9	08-03-2023	06-30-2023	10-Q
10	05-04-2023	03-31-2023	10-Q
11	02-23-2023	12-31-2022	10-K
12	11-03-2022	09-30-2022	10-Q
13	08-09-2022	06-30-2022	10-Q
14	05-03-2022	03-31-2022	10-Q
15	02-24-2022	12-31-2021	10-K
16	11-10-2021	09-30-2021	10-Q
17	08-06-2021	06-30-2021	10-Q
18	05-06-2021	03-31-2021	10-Q
19	03-11-2021	12-31-2020	10-K
20	11-05-2020	09-30-2020	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

BTIG Maintains Buy on Kymera Therapeutics,...
10/22/2025 11:34:23

BTIG analyst Jeet Mukherjee maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $59 to ...

Mizuho Initiates Coverage On Kymera Therap...
10/21/2025 12:38:26

Mizuho analyst Joseph Catanzaro initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Outperform rating and announc...

The Analyst Verdict: Kymera Therapeutics I...
10/17/2025 18:01:08

Citigroup Maintains Buy on Kymera Therapeu...
10/17/2025 15:24:56

Citigroup analyst Geoff Meacham maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $60 ...

Oppenheimer Maintains Outperform on Kymera...
10/01/2025 13:37:12

Oppenheimer analyst Jeff Jones maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and raises the price target fro...

Truist Securities Maintains Buy on Kymera ...
09/30/2025 14:32:05

Truist Securities analyst Srikripa Devarakonda maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price t...

HC Wainwright & Co. Maintains Buy on Kymer...
09/18/2025 13:52:32

HC Wainwright & Co. analyst Andrew S. Fein maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price t...

Kymera Advances Oral STAT6 Degrader Toward...
09/17/2025 11:09:08

Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecul...

Barclays Initiates Coverage On Kymera Ther...
09/17/2025 10:53:30

Barclays analyst Etzer Darout initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Overweight rating and announces...

Breaking Down Kymera Therapeutics: 4 Analy...
09/16/2025 21:01:18

this-chubb-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-tuesday

This Chubb Analyst Begins Coverage On A Bu...
09/16/2025 13:22:50

RBC Capital Initiates Coverage On Kymera T...
09/16/2025 13:02:19

RBC Capital analyst Brian Abrahams initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Outperform rating and anno...

Kymera Therapeutics Q2 EPS $(0.95) Misses ...
08/11/2025 11:04:34

Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of...

Earnings Scheduled For August 11, 2025
08/11/2025 08:32:28

What to Expect from Kymera Therapeutics's ...
08/08/2025 15:01:29

synovus-financial-gilead-sciences-and-more-on-cnbcs-final-trades

Synovus Financial, Gilead Sciences And Mor...
07/09/2025 12:14:04

Insights from strategists and analysts can greatly influence market sentiment and investment strategies. CNBC's Halftime Re...

Oppenheimer Maintains Outperform on Kymera...
06/27/2025 17:39:25

Oppenheimer analyst Jeff Jones maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and lowers the price target fro...

Reported Earlier, Kymera Therapeutics Pric...
06/27/2025 06:12:49

Wells Fargo Maintains Overweight on Kymera...
06/26/2025 14:19:14

Wells Fargo analyst Derek Archila maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and lowers the price target ...

Beyond The Numbers: 8 Analysts Discuss Kym...
06/26/2025 14:00:32